NGL Fine-Chem Limited (NGLFINE) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of NGL Fine-Chem Limited ₹1,324, price ₹2,924, upside -54.7%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch NGL Fine-Chem Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
51‑month range ₹981.15 – ₹3,456 · fair‑value band ₹993.22 – ₹1,659 · the ₹2,924 price screens above the ₹1,324 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow NGL Fine-Chem in your weekly email
Every Wednesday you see whether NGL Fine-Chem is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally.
Show more
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, fenbendazole, and xylazine hydrochloride. It also provides human health pharmaceutical ingredients, including nitazoxanide and atovaquone; and intermediates and specialty chemicals comprising 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-ethyl glucamine. In addition, the company offers finished dosage forms, including diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.
Stock analysis
NGL Fine-Chem Limited (NGLFINE) currently trades at ₹2,924, while our model-based Fair Value estimate is ₹1,324, 54.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹2,236 per share, and 1 of the 16 models we run sit above the ₹2,924 price.
Bear case: the Asset-Based group reads lowest at ₹357.05, and 15 of the 16 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹993.22 (bear) to ₹1,659 (bull), the price of ₹2,924 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
NGL Fine-Chem Limited reported revenue of ₹5.0B in FY2026 versus ₹3.2B in FY2022, a compound +12.1%/yr. Reported net income was ₹481M in FY2026, compounding −0.9%/yr from FY2022.
Key figures
Market cap ₹18.1B (≈ $188M) · P/E ratio 31.5 · P/S ratio 3.03 · EPS (TTM) ₹92.81 · Dividend yield 0.1% · Net margin 9.6% · Return on equity 15.7% · Return on assets (EBIT) 11.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 15% below its 52-week high and 129% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −55%, NGLFINE screens richer than that median.
Fair Value models
Bear ₹993.22Fair Value ₹1,324Bull ₹1,659
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹46.15 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+36.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.2%
Start year 2021 (pandemic). Over 10 years: +17.9% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.7%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−8.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−9.0%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.7% vs 15.5%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.29% → 11%
2026 sits 128% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−54.7% · Bottom 25%
Profitability
Return on equity (TTM)15.7% · Above median
Return on assets6.8% · Above median
Net margin (TTM)10.7% · Below median
Operating margin (TTM)13.0% · Below median
Growth and dividend
Revenue growth33.6% · Top 25%
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity0.17× · Above median
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
P/E (TTM)31.5× · Pricier than median
P/B5.49× · Priciest 25%
P/S (TTM)3.37× · Pricier than median
EV/EBITDA21.8× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 21
FUTURE (revenue growth)100· sector 32
PAST (return on equity)63· sector 41
HEALTH (low debt)91· sector 92
DIVIDEND (yield)1· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is NGL Fine-Chem Limited (NGLFINE) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ₹1,324 versus a price of ₹2,924, about −55% upside (overvalued).
What is the fair value of NGLFINE?
Our model-based fair value for NGL Fine-Chem Limited is ₹1,324 (as of Oct 2, 2026), built from audited fundamentals. The current price: ₹2,924.
What is the quality score of NGLFINE?
NGL Fine-Chem Limited has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NGL Fine-Chem Limited (NGLFINE)?
Our model-based price target is the fair value of ₹1,324 (as of Oct 2, 2026) from 16 valuation models. Cautious scenario ₹993.22, optimistic scenario ₹1,659. It is a calculation from audited fundamentals, not an analyst target.
What is the NGL Fine-Chem Limited stock forecast for 2026?
Our models put fair value at ₹1,324, about −55% upside versus a price of ₹2,924 (overvalued). Cautious scenario ₹993.22, optimistic scenario ₹1,659. The calculation is refreshed regularly with new filings.
What is the revenue of NGL Fine-Chem Limited (NGLFINE)?
NGL Fine-Chem Limited reported trailing-twelve-month revenue of about ₹5.4B (latest available figure, as of Oct 2, 2026).
Does NGL Fine-Chem Limited pay a dividend?
NGL Fine-Chem Limited currently shows a dividend yield of about 0.06% relative to its recent price (as of Oct 2, 2026).
What is the intrinsic value of NGL Fine-Chem Limited (NGLFINE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NGL Fine-Chem Limited it is ₹1,324 per share (as of Oct 2, 2026), against a price of ₹2,924. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is NGL Fine-Chem Limited stock overvalued or undervalued in 2026?
As of Oct 2, 2026, NGLFINE trades above its calculated fair value: price ₹2,924, fair value ₹1,324, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NGLFINE?
No. The price is what the market pays today (₹2,924); the fair value is what the company's own numbers justify (₹1,324). For NGL Fine-Chem Limited the two are ₹1,600 per share apart. That gap is exactly why we show both numbers side by side.
How much is NGL Fine-Chem Limited worth?
The market values NGL Fine-Chem Limited at about ₹18.1B (market capitalisation, as of Oct 2, 2026). Per share that is ₹2,924; our models calculate a fair value of ₹1,324 per share.
What do the bullish and bearish scenarios say about NGLFINE?
Our models span a range for NGL Fine-Chem Limited: cautious scenario ₹993.22, base ₹1,324, optimistic ₹1,659 per share (as of Oct 2, 2026, price ₹2,924). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NGLFINE?
NGL Fine-Chem Limited trades at a price-to-earnings ratio of 31.5 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹1,324 is built from several models across several years. Other multiples: P/B 5.5, P/S 3.4, EV/EBITDA 21.8.
How solid is the balance sheet of NGL Fine-Chem Limited (NGLFINE)?
Balance-sheet figures for NGL Fine-Chem Limited (as of Oct 2, 2026): return on equity 15.7%, debt of 0.17 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is NGLFINE from its 52-week high?
NGL Fine-Chem Limited trades at ₹2,924, about 15% below its 52-week high of ₹3,456 and 129% above the low of ₹1,278 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1,324 is for.
Which stocks are comparable to NGL Fine-Chem Limited?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NGL Fine-Chem Limited stock attractive at the current price?
The data as of Oct 2, 2026: price ₹2,924, calculated fair value ₹1,324 (−55%), Quality Score 53/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NGLFINE calculated?
We run NGL Fine-Chem Limited through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹1,324, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. NGL Fine-Chem Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NGL Fine-Chem Limited (NGLFINE)?
The closing price on Oct 1, 2026 was ₹2,924. Our model-based fair value is ₹1,324, about −55% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NGL Fine-Chem Limited right now?
The price sits above even our optimistic bull case (₹1,659). The favourable scenario is already priced in. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of NGL Fine-Chem Limited (NGLFINE) come from?
Earnings per share at NGL Fine-Chem Limited grew +14.0 % a year from 2015 to 2026. Broken into its drivers: revenue per share +17.4 %, EBIT margin −7.1 %, tax rate +1.9 %, residual (interest, one-offs) +2.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of NGL Fine-Chem Limited
How large is the market capitalisation of NGL Fine-Chem Limited (NGLFINE)?
The market capitalisation of NGL Fine-Chem Limited is ₹18.1B (≈ $188M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NGL Fine-Chem Limited (NGLFINE)?
The price-to-sales ratio of NGL Fine-Chem Limited is 3.03 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of NGL Fine-Chem Limited (NGLFINE)?
Earnings per share at NGL Fine-Chem Limited are ₹92.81 (price ÷ EPS = P/E 31.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of NGL Fine-Chem Limited (NGLFINE)?
The dividend yield of NGL Fine-Chem Limited is 0.1% (payout 1.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of NGL Fine-Chem Limited (NGLFINE)?
The net margin of NGL Fine-Chem Limited is 9.6% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NGL Fine-Chem Limited (NGLFINE)?
The return on equity (ROE) of NGL Fine-Chem Limited is 15.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NGL Fine-Chem Limited (NGLFINE)?
On an EBIT basis the return on assets of NGL Fine-Chem Limited is 11.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NGL Fine-Chem Limited (NGLFINE)?
The operating margin of NGL Fine-Chem Limited is 13.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NGL Fine-Chem Limited (NGLFINE)?
Revenue at NGL Fine-Chem Limited is growing +33.6% versus a year earlier (3y avg +21.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at NGL Fine-Chem Limited (NGLFINE)?
Earnings per share at NGL Fine-Chem Limited are growing +99.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does NGL Fine-Chem Limited (NGLFINE) generate?
The free cash flow of NGL Fine-Chem Limited is −₹503M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does NGL Fine-Chem Limited (NGLFINE) carry?
The net debt of NGL Fine-Chem Limited is ₹1.0B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch NGL Fine-Chem Limited in the live analysis
One click puts NGL Fine-Chem Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
